News

Novartis has agreed to acquire UK-based biotechnology company Myricx Bio for an upfront payment of $1.1 billion, with up to $400 million in additional milestone payments, as it looks to…
Read More...

AbbVie has received European Commission marketing authorization for TEPKINLY, or epcoritamab, in combination with lenalidomide and rituximab for adults with relapsed or refractory…
Read More...

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in an all-cash transaction valued at approximately $10 billion, expanding Vertex’s presence in rare endocrine…
Read More...

Arcturus Therapeutics has entered into a strategic collaboration with Thermo Fisher Scientific to support the late-stage development and potential commercialization of ARCT-032, an…
Read More...

Lonza has acquired rights to Nona Biosciences’ transferrin receptor 1, or TfR1, blood-brain barrier technology, expanding its capabilities in central nervous system drug development and…
Read More...

Ipsen has agreed to acquire Memo Therapeutics AG in a deal designed to strengthen its rare disease pipeline with potravitug, a Phase II clinical-stage monoclonal antibody for BK…
Read More...

AlzeCure Pharma AB has signed an out-licensing and collaboration agreement with Danish biotech company QuantumCell ApS for the global rights to its NeuroRestore platform, including its…
Read More...

Inocras Inc. and AimedBio have entered into a strategic partnership focused on using whole genome sequencing and multi-omics data to accelerate the development of antibody-drug…
Read More...

Insilico Medicine has entered into a strategic collaboration with Takeda Pharmaceutical Company to accelerate AI-driven drug discovery, leveraging its proprietary Pharma.AI platform to…
Read More...

Novartis has received European Commission approval for Itvisma® (onasemnogene abeparvovec), expanding access to gene replacement therapy for children, teenagers and adults living with…
Read More...

Sanofi has reported positive Phase 3 results for Nexviazyme, also known as avalglucosidase alfa, in infants with infantile-onset Pompe disease, a rare and life-threatening genetic…
Read More...

Vertex Pharmaceuticals has received expanded approval from the U.S. Food and Drug Administration for CASGEVY® (exagamglogene autotemcel), allowing the gene-editing therapy to be used in…
Read More...

Innovent Biologics and Eli Lilly and Company have entered into a new distribution and promotion agreement for Verzenios® (abemaciclib) in mainland China, expanding their commercial…
Read More...

Zymeworks Inc. has agreed to acquire Theravance Biopharma, Inc. in an all-cash transaction valued at approximately $929 million, marking a significant consolidation in the biotechnology…
Read More...

Eli Lilly and Company has moved a step closer to expanding the use of its blood cancer therapy Jaypirca (pirtobrutinib) in Europe after receiving a positive opinion from the European…
Read More...

Talawar Tx Inc., a biotechnology company developing next-generation bispecific antibody therapies for immunology and inflammatory diseases, has signed a definitive business combination…
Read More...

AstraZeneca and YMCA of the USA (Y-USA) have launched a five-year, multimillion-dollar partnership aimed at improving cancer awareness, increasing screening and early detection rates,…
Read More...

Antares Therapeutics has entered into a strategic collaboration with Novartis to discover, develop, and commercialize a new generation of small-molecule cancer therapies targeting…
Read More...

Ionis Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for TRYNGOLZA (olezarsen), a first-of-its-kind therapy designed to reduce triglyceride levels and…
Read More...

RQ Bio has secured $115 million (£85.5 million) in an oversubscribed Series A financing, providing the biotechnology company with significant resources to advance the clinical…
Read More...